Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1994 1
2003 1
2004 1
2005 1
2006 3
2007 6
2008 4
2009 3
2010 8
2011 5
2012 4
2013 4
2014 3
2015 12
2016 3
2017 5
2018 4
2019 7
2020 1
2022 6
2023 6
2024 3

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

82 results

Results by year

Filters applied: . Clear all
Page 1
A Review of Autologous Stem Cell Transplantation in Lymphoma.
Zahid U, Akbar F, Amaraneni A, Husnain M, Chan O, Riaz IB, McBride A, Iftikhar A, Anwer F. Zahid U, et al. Curr Hematol Malig Rep. 2017 Jun;12(3):217-226. doi: 10.1007/s11899-017-0382-1. Curr Hematol Malig Rep. 2017. PMID: 28478586 Free PMC article. Review.
RECENT FINDINGS: There is some utility of upfront consolidation for-high risk/high-grade B-cell lymphoma, mantle cell lymphoma, and T-cell lymphoma, but there is no role of similar intervention for HL. New conditioning regimens are being investigated which have demonstrate …
RECENT FINDINGS: There is some utility of upfront consolidation for-high risk/high-grade B-cell lymphoma, mantle cell lymphoma, and T …
Donor origin CAR T cells: graft versus malignancy effect without GVHD, a systematic review.
Anwer F, Shaukat AA, Zahid U, Husnain M, McBride A, Persky D, Lim M, Hasan N, Riaz IB. Anwer F, et al. Immunotherapy. 2017 Jan;9(2):123-130. doi: 10.2217/imt-2016-0127. Immunotherapy. 2017. PMID: 28128714 Free PMC article. Review.
CD19, CD20 chimeric antigen receptor T (CAR T) cell therapy has shown promising results for the treatment of relapsed or refractory hematological malignancies. ...A total of 72 patients from seven studies were treated with donor-derived CAR T cells. Only five …
CD19, CD20 chimeric antigen receptor T (CAR T) cell therapy has shown promising results for the treatment of relapsed or refra …
Chimeric Antigen Receptor T-Cell (CAR T-Cell) Therapy for Primary and Secondary Central Nervous System Lymphoma: A Systematic Review of Literature.
Asghar N, Masood A, Dhaliwal A, Khurana S, Davis J, Hashmi H, Husnain M. Asghar N, et al. Clin Lymphoma Myeloma Leuk. 2023 Jan;23(1):15-21. doi: 10.1016/j.clml.2022.09.008. Epub 2022 Oct 7. Clin Lymphoma Myeloma Leuk. 2023. PMID: 36328891 Review.
In the real-world experience, chimeric antigen receptor T-cell (CAR T) therapy has been deemed safe and effective for these patients with poor prognosis. ...A total of 14 studies, including 8 retrospective analyses and 6 prospective studies/clinical trials, were inc …
In the real-world experience, chimeric antigen receptor T-cell (CAR T) therapy has been deemed safe and effective for these pa …
A systematic review and meta-analysis on utilizing anti-CD19 chimeric antigen receptor T-cell therapy as a second-line treatment for relapsed and refractory diffuse large B-cell lymphoma.
Asghar K, Zafar M, Holland E, Abduljabbar AB, Albagoush SA, Asghar N, Sood A, Dufani JM, Thirumalaredy J, DeVrieze B, Tauseef A, Husnain M. Asghar K, et al. Front Oncol. 2024 Jul 18;14:1407001. doi: 10.3389/fonc.2024.1407001. eCollection 2024. Front Oncol. 2024. PMID: 39091918 Free PMC article.
INTRODUCTION: Inconsistent results observed in recent phase III trials assessing chimeric antigenic receptor T (CAR-T) cell therapy as a second-line treatment compared to standard of care (SOC) in patients with relapsed/refractory diffuse large B-cell lymphoma (R/R …
INTRODUCTION: Inconsistent results observed in recent phase III trials assessing chimeric antigenic receptor T (CAR-T) cell th …
Has the shortage of fludarabine altered the current paradigm of lymphodepletion in favor of bendamustine?
Filioglou D, Husnain M, Khurana S, Simpson RJ, Katsanis E. Filioglou D, et al. Front Immunol. 2023 Nov 22;14:1329850. doi: 10.3389/fimmu.2023.1329850. eCollection 2023. Front Immunol. 2023. PMID: 38077398 Free PMC article. Review.
The most common lymphodepletion regimen used prior to infusion of chimeric antigen receptor-T cells (CAR-T) is cyclophosphamide (CY) in combination with fludarabine (Flu) (CY-FLU). While cyclophosphamide (CY) possesses lymphotoxic effects, it concurrently preserves …
The most common lymphodepletion regimen used prior to infusion of chimeric antigen receptor-T cells (CAR-T) is cyclophosphamid …
Anti-CD 19 and anti-CD 20 CAR-modified T cells for B-cell malignancies: a systematic review and meta-analysis.
Riaz IB, Zahid U, Kamal MU, Husnain M, McBride A, Hua A, Hamadani AA, George L, Zeeshan A, Sipra QR, Raina A, Rahman B, Puvvada S, Anwer F. Riaz IB, et al. Immunotherapy. 2017 Sep;9(12):979-993. doi: 10.2217/imt-2017-0062. Immunotherapy. 2017. PMID: 28971751 Free PMC article. Review.
Chimeric antigen receptor modified T cells targeting CD19 and CD20 have shown activity in Phase I, II trials of patients with hematological malignancies. We conducted a systematic review and meta-analysis of all published clinical trials studying the role of efficacy as we …
Chimeric antigen receptor modified T cells targeting CD19 and CD20 have shown activity in Phase I, II trials of patients with hematol …
HIV Diagnosis and Treatment through Advanced Technologies.
Zulfiqar HF, Javed A, Sumbal, Afroze B, Ali Q, Akbar K, Nadeem T, Rana MA, Nazar ZA, Nasir IA, Husnain T. Zulfiqar HF, et al. Front Public Health. 2017 Mar 7;5:32. doi: 10.3389/fpubh.2017.00032. eCollection 2017. Front Public Health. 2017. PMID: 28326304 Free PMC article. Review.
It infects different cells of the immune system, such as CD4+ T cells (T-helper cells), dendritic cells, and macrophages. HIV has two subtypes: HIV-1 and HIV-2. ...
It infects different cells of the immune system, such as CD4+ T cells (T-helper cells), dendritic cells, and macrophages. HIV …
Oncolytic virotherapy including Rigvir and standard therapies in malignant melanoma.
Babiker HM, Riaz IB, Husnain M, Borad MJ. Babiker HM, et al. Oncolytic Virother. 2017 Feb 9;6:11-18. doi: 10.2147/OV.S100072. eCollection 2017. Oncolytic Virother. 2017. PMID: 28224120 Free PMC article. Review.
This is certainly a burgeoning time in immunotherapy drug development, and the aforementioned efforts along with the recent US Food and Drug Administration approval of talimogene laherparepvec (T-VEC), a recombinant oncolytic herpes virus, have paved the way to exploring t …
This is certainly a burgeoning time in immunotherapy drug development, and the aforementioned efforts along with the recent US Food and Drug …
82 results